1. Home
  2. Drugs
  3. Development & Approval Process | Drugs
  4. Drug Approvals and Databases
  5. Resources for Information | Approved Drugs
  6. Drug Information Soundcast in Clinical Oncology (D.I.S.C.O.)
  1. Resources for Information | Approved Drugs

Drug Information Soundcast in Clinical Oncology (D.I.S.C.O.)

FDA DISCO Podcast Image

FDA Drug Information Soundcast in Clinical Oncology (DISCO) is an FDA podcast series that provides information about new product approvals, emerging safety information for cancer treatments, and other current topics in cancer drug development.

Listen on Apple Podcasts

Listen on YouTube Podcasts

Listen on Spotify Podcasts

Latest Drug Information Soundcasts

TitleDateLink to PodcastLink to Transcript
FDA D.I.S.C.O. Burst Edition: Bizengri (zenocutuzumab-zbco)
FDA approval of Bizengri (zenocutuzumab-zbco) for adults with advanced, unresectable, or metastatic non-small cell lung cancer or pancreatic adenocarcinoma harboring a NRG1 gene fusion with disease progression on or after prior systemic therapy.		December 30, 2024Listen
Run Time: 00:02:59		Transcript
FDA D.I.S.C.O. Burst Edition: Ryoncil (remestemcel-L-rknd)
FDA approval of Ryoncil (remestemcel-L-rknd) for steroid-refractory acute graft versus host disease in pediatric patients		December 18, 2024Listen
Run Time: 00:03:00		Transcript
FDA D.I.S.C.O. Burst Edition: Keytruda (pembrolizumab)
FDA approval of Keytruda (pembrolizumab) for unresectable advanced or metastatic malignant pleural mesothelioma		September 17, 2024Listen
Run Time: 00:03:30		Transcript
FDA D.I.S.C.O. Burst Edition: Tecelra (afamitresgene autoleucel)
FDA approval of Tecelra (afamitresgene autoleucel) for unresectable or metastatic synovial sarcoma		August 2, 2024Listen
Run Time: 00:03:30		Transcript
FDA D.I.S.C.O. Burst Edition: Augtyro (repotrectinib) and Krazati (adagrasib)
FDA approvals of Augtyro (repotrectinib) for NTRK gene fusion-positive solid tumors and Krazati (adagrasib) for KRAS G12C-mutated colorectal cancer		June 13, 2024Listen
Run Time: 00:04:59		Transcript
FDA D.I.S.C.O. Burst Edition: Retevmo (selpercatinib)
FDA approval of Retevmo (selpercatinib) for advanced or metastatic RET fusion-positive thyroid cancer		May 29, 2024Listen
Run Time: 00:04:00		Transcript
FDA D.I.S.C.O. Burst Edition: Ojemda (tovorafenib)
FDA approval of Ojemda (tovorafenib) for relapsed or refractory pediatric low-grade glioma harboring a BRAF fusion or rearrangement, or BRAF V600 mutation		April 23, 2024Listen
Run Time: 00:04:00		Transcript
FDA D.I.S.C.O. Burst Edition: Enhertu (fam-trastuzumab deruxtecan-nxki)
FDA approval of Enhertu (fam-trastuzumab deruxtecan-nxki) for unresectable or metastatic HER2-positive solid tumors		April 5, 2024Listen
Run Time: 00:03:30		Transcript
FDA D.I.S.C.O. Burst Edition: OGSIVEO (nirogacestat)
FDA approval of OGSIVEO (nirogacestat) for adult patients with progressing desmoid tumors who require systemic treatment		November 27, 2023Listen
Run Time: 00:03:30		Transcript
FDA D.I.S.C.O. Burst Edition: Augtyro (repotrectinib)
FDA approval of Augtyro (repotrectinib) for locally advanced or metastatic ROS1-positive non-small cell lung cancer		November 15, 2023Listen
Run Time: 00:02:59		Transcript
FDA D.I.S.C.O. Burst Edition: Fruzaqla (fruquintinib)
FDA approval of Fruzaqla (fruquintinib) for adult patients with metastatic colorectal cancer		November 8, 2023Listen
Run Time: 00:03:30		Transcript
FDA D.I.S.C.O. Burst Edition: Tibsovo (ivosidenib)
FDA approval of Tibsovo (ivosidenib) for patients with relapsed or refractory myelodysplastic syndromes with a susceptible isocitrate dehydrogenase-1 mutation		October 24, 2023Listen
Run Time: 00:03:30		Transcript
FDA D.I.S.C.O. Burst Edition: Talvey (talquetamab-tgvs) and Elrexfio (elranatamab-bcmm)
FDA approvals of Talvey (talquetamab-tgvs) for relapsed or refractory multiple myeloma, and Elrexfio (elranatamab-bcmm) for relapsed or refractory multiple myeloma		August 2, 2023Listen
Run Time: 00:06:59		Transcript
FDA D.I.S.C.O. Burst Edition: Lynparza (olaparib)
FDA approval of Lynparza (olaparib), with abiraterone and prednisone, for BRCA-mutated metastatic castration-resistant prostate cancer		May 31, 2023Listen
Run Time: 00:03:30		Transcript
FDA D.I.S.C.O. Burst Edition: Epkinly (epcoritamab-bysp)
FDA approval of Epkinly (epcoritamab-bysp) for relapsed or refractory diffuse large B-cell lymphoma and high-grade B-cell lymphoma		May 19, 2023Listen
Run Time: 00:03:30		Transcript
FDA D.I.S.C.O. Burst Edition:  Polivy (polatuzumab vedotin-piiq)
FDA approval of Polivy (polatuzumab vedotin-piiq) for previously untreated diffuse large B-cell lymphoma, not otherwise specified, and high-grade B-cell lymphoma		April 19, 2023Listen
Run Time: 00:03:30		Transcript
FDA D.I.S.C.O. Burst Edition: Omisirge (omidubicel-onlv)
FDA approval of Omisirge (omidubicel-onlv) to reduce time to neutrophil recovery and infection in patients with hematologic malignancies		April 17, 2023Listen
Run Time: 00:03:30		Transcript
FDA D.I.S.C.O. Burst Edition: Padcev (enfortumab vedotin-ejfv) with Keytruda (pembrolizumab)
FDA approval of Padcev (enfortumab vedotin-ejfv) with Keytruda (pembrolizumab) for locally advanced or metastatic urothelial carcinoma		April 3, 2023Listen
Run Time: 00:04:00		Transcript
FDA D.I.S.C.O. Burst Edition: Zynyz (retifanlimab-dlwr)
FDA approval of Zynyz (retifanlimab-dlwr) for metastatic or recurrent locally advanced Merkel cell carcinoma		March 22, 2023Listen
Run Time: 00:02:29		Transcript
FDA D.I.S.C.O. Burst Edition: Tafinlar (dabrafenib) with Mekinist (trametinib)
FDA approval of Tafinlar (dabrafenib) with Mekinist (trametinib) for pediatric patients with low-grade glioma with a BRAF V600E mutation		March 16, 2023Listen
Run Time: 00:04:00		Transcript
FDA D.I.S.C.O. Burst Edition: Verzenio (abemaciclib)
FDA approval of Verzenio (abemaciclib) with endocrine therapy for patients with HR-positive, HER2-negative, node-positive, early breast cancer		March 3, 2023Listen
Run Time: 00:04:30		Transcript
FDA D.I.S.C.O. Burst Edition: Jemperli (dostarlimab-gxly)
FDA approval of Jemperli (dostarlimab-gxly) for dMMR endometrial cancer		February 9, 2023Listen
Run Time: 00:03:30		Transcript
FDA D.I.S.C.O. Burst Edition: Trodelvy (sacituzumab govitecan-hziy)
FDA approval of Trodelvy (sacituzumab govitecan-hziy) for HR-positive breast cancer		February 3, 2023 Listen
Run Time: 00:04:00		Transcript
FDA D.I.S.C.O. Burst Edition: Jaypirca (pirtobrutinib) and Orserdu (elacestrant)
FDA approvals of Jaypirca (pirtobrutinib) for relapsed or refractory mantle cell lymphoma, and Orserdu (elacestrant) for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer		January 27, 2023Listen
Run Time: 00:06:59		Transcript
FDA D.I.S.C.O. Burst Edition: Keytruda (pembrolizumab)
FDA approval of Keytruda (pembrolizumab) as adjuvant treatment for non-small cell lung cancer		January 26, 2023Listen
Run Time: 00:03:30		Transcript
FDA D.I.S.C.O. Burst Edition: Tukysa (tucatinib) and Brukinsa (zanubrutinib)
FDA approvals of Tukysa (tucatinib) with trastuzumab for colorectal cancer and Brukinsa (zanubrutinib) for chronic lymphocytic leukemia or small lymphocytic lymphoma		January 19, 2023Listen
Run Time: 00:06:29		Transcript
FDA D.I.S.C.O. Burst Edition: Lunsumio (mosunetuzumab-axgb)
FDA approval of Lunsumio (mosunetuzumab-axgb) for adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy		December 22, 2022Listen
Run Time: 00:03:30		Transcript
FDA D.I.S.C.O. Burst Edition: Adstiladrin (nadofaragene firadenovec-vncg)
FDA approval of Adstiladrin (nadofaragene firadenovec-vncg) for patients with high-risk Bacillus Calmette-Guérin unresponsive non-muscle invasive bladder cancer with carcinoma in situ with or without papillary tumors		December 16, 2022Listen
Run Time: 00:03:30		Transcript
FDA D.I.S.C.O. Burst Edition: Xeloda (capecitabine)
FDA approves updated drug labeling including new indications and dosing regimens for Xeloda (capecitabine) tablets under Project Renewal		December 14, 2022Listen
Run Time: 00:04:00		Transcript
FDA D.I.S.C.O. Burst Edition: Tecentriq (atezolizumab) and Krazati (adagrasib)
FDA approvals of Tecentriq (atezolizumab) for unresectable or metastatic alveolar soft part sarcoma, and Krazati (adagrasib) for KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer		December 9, 2022Listen
Run Time: 00:06:59		Transcript
FDA D.I.S.C.O. Burst Edition: Rezlidhia (olutasidenib)
FDA approval of Rezlidhia (olutasidenib) for relapsed or refractory acute myeloid leukemia with a susceptible IDH1 mutation		December 1, 2022Listen
Run Time: 00:03:30		Transcript
FDA D.I.S.C.O. Burst Edition: Elahere (mirvetuximab soravtansine-gynx)
FDA approval of Elahere (mirvetuximab soravtansine-gynx) for FRα positive, platinum-resistant epithelial ovarian, fallopian tube, or peritoneal cancer		November 14, 2022Listen
Run Time: 00:04:00		Transcript

 

Additional Information

Back to Top